Evommune reports Phase 2a data for EVO301 in atopic dermatitis at EADV

Evommune, Inc. (NYSE: EVMN) disclosed on October 1, 2026 that it presented new findings from its Phase 2a proof-of-concept study of EVO301 in adults with moderate-to-severe atopic dermatitis during a late-breaking session at the European Academy of Dermatology and Venereology Congress in Vienna, Austria.

EVO301 is a long-acting injectable fusion protein designed to selectively inhibit overactive IL-18, with the potential to offer broader upstream pathway control than standard-of-care biologics.¹ The trial enrolled 70 patients to evaluate intravenous dosing of 5mg/kg at baseline and week 4, with 48 on active treatment and 22 on placebo, and a primary endpoint set at week 12, eight weeks after the last dose.¹

The study met its primary goal. EVO301 achieved a 55% least-squares mean reduction in EASI from baseline at Week 12, compared with 22% on placebo, with a p-value under 0.01.¹ The separation from placebo was statistically significant as early as Week 4 (41% versus 18%) and continued through Week 8 (50% versus 16%) and Week 12, with p<0.01 at each point.¹

Response rates followed a similar pattern: 63% of EVO301 patients reached EASI-50 at Week 12 versus 23% on placebo, while EASI-75 rates reached 29% versus 9% on placebo at the same timepoint.¹

On safety, the company said EVO301 was well tolerated, with no treatment-related serious or severe adverse events, no discontinuations from adverse events, no significant lab abnormalities, and no conjunctivitis, and that treatment-related adverse events occurred in 10.4% of EVO301 patients versus 13.6% on placebo.¹

Pharmacokinetic data were described as consistent with Phase 1 results and supportive of a once-every-4-week dosing schedule, with potential for maintenance dosing every 8 to 12 weeks.¹

Evommune said it plans to move into a global Phase 2b trial using a dose-optimized subcutaneous formulation, targeted to begin in mid-2027.¹